Cholecystokinin (CCK)
Cholecystokinin (CCK) is a gut-brain peptide existing in multiple bioactive forms (CCK-8, CCK-33, CCK-58) that signals through CCK-A (peripheral) and CCK-B (CNS) receptors. It mediates gallbladder contraction, pancreatic secretion, satiety, and anxiety/panic responses, with CCK-4 serving as a validated panic-induction model.
Overview
CCK is produced by I-cells in the duodenal and jejunal mucosa in response to intraluminal fat and protein, and by neurons throughout the central nervous system where it functions as a neurotransmitter. It is one of the most abundant neuropeptides in the brain, with particularly dense expression in the cerebral cortex, hippocampus, amygdala, and periaqueductal gray. The biological activity of all CCK forms resides in the C-terminal octapeptide sequence (CCK-8), and sulfation of the tyrosine residue at position 7 (from the C-terminus) is essential for full CCK-A receptor activity.
CCK-A receptors (also designated CCK₁) are predominantly expressed in the periphery — gallbladder, pancreas, vagal afferents, and some brainstem nuclei — mediating digestive and satiety functions. CCK-B receptors (CCK₂), identical to gastrin receptors, are widely distributed in the CNS and mediate anxiety, panic, memory, and nociceptive effects. This receptor distribution creates a clear functional dichotomy between CCK's peripheral digestive roles and its central neuropsychiatric actions.
Mechanism of Action
CCK signals through two G-protein-coupled receptors with distinct distributions and coupling:
- CCK-A (CCK₁) receptor: Couples to Gq → PLC → IP₃/DAG → Ca²⁺ release. High affinity for sulfated CCK-8 (1000-fold selectivity over unsulfated form). Mediates gallbladder contraction, pancreatic enzyme secretion, and vagal afferent satiety signaling. Located on gallbladder smooth muscle, pancreatic acinar cells, vagal afferents, and pyloric sphincter Dufresne et al. (2006).
- CCK-B (CCK₂) receptor: Also couples to Gq → PLC → Ca²⁺. Equal affinity for sulfated and unsulfated CCK and for gastrin. Widely expressed in brain (cortex, amygdala, hippocampus, nucleus accumbens) and on gastric ECL cells. Mediates anxiety/panic responses, memory modulation, and gastric acid secretion Noble et al. (1999).
- Vagal satiety pathway: CCK released from I-cells activates CCK-A receptors on vagal afferent terminals in the duodenal mucosa, transmitting satiety signals to the nucleus of the solitary tract (NTS) → hypothalamus. This is the primary acute meal-termination pathway Moran & Kinzig (2004).
- Opioid interaction: CCK-B receptor activation opposes opioid analgesia. Endogenous CCK release during sustained opioid exposure contributes to analgesic tolerance. CCK-B antagonists potentiate and prolong opioid analgesia Faris et al. (1983).
Reconstitution Calculator
Research
Analgesic Interactions with Opioids
CCK functions as an endogenous anti-opioid peptide. CCK-B receptor activation in the periaqueductal gray, rostral ventromedial medulla, and spinal cord opposes opioid-mediated analgesia Faris et al. (1983). Opioid administration upregulates CCK expression, and this CCK release contributes to the development of opioid tolerance and hyperalgesia. CCK-B receptor antagonists (proglumide, L-365,260) potentiate morphine analgesia, prevent tolerance development, and enhance the analgesic efficacy of endogenous opioids. This CCK-opioid interaction has therapeutic implications for pain management and the design of combination analgesic strategies.
Gallbladder Contraction and Pancreatic Secretion
CCK is the primary physiological stimulus for gallbladder contraction and pancreatic enzyme secretion. Postprandial CCK release triggers coordinated gallbladder contraction, sphincter of Oddi relaxation, and pancreatic acinar cell degranulation, delivering bile and digestive enzymes to the duodenum. Sincalide (CCK-8, Kinevac) is FDA-approved as a diagnostic agent for cholecystography and pancreatic function testing Liddle et al. (1985). CCK dysregulation is implicated in functional gallbladder disorder and chronic pancreatitis, and CCK-A receptor polymorphisms have been associated with gallstone disease susceptibility.
CCK-4 and Panic Disorder
CCK-4 (the C-terminal tetrapeptide Trp-Met-Asp-Phe-NH₂) is the most validated pharmacological model for panic attacks in humans. Intravenous CCK-4 administration (25–50 µg) reliably induces panic symptoms — palpitations, dyspnea, derealization, fear of dying — in panic disorder patients and healthy volunteers, with panic disorder patients showing heightened sensitivity Bradwejn et al. (1991). This effect is mediated by CCK-B receptors in the amygdala and brainstem. The CCK-4 challenge has been used extensively to study panic neurobiology, test anxiolytic efficacy, and investigate genetic vulnerability to anxiety disorders. CCK-B receptor antagonists (e.g., L-365,260, CI-988) have shown anxiolytic effects in preclinical models but have not achieved clinical success due to pharmacokinetic limitations.
Memory and Cognition
CCK modulates memory through CCK-B receptors in the hippocampus and amygdala. CCK enhances long-term potentiation (LTP) at hippocampal synapses and facilitates memory consolidation in fear conditioning and spatial learning paradigms. CCK-expressing interneurons in the hippocampus coordinate network oscillations critical for memory encoding. Dysregulation of CCK signaling has been implicated in cognitive decline associated with Alzheimer's disease, schizophrenia, and age-related memory impairment Bhatt et al. (2021).
CCK-4 panic challenge model in drug development
The cholecystokinin tetrapeptide (CCK-4) challenge is a validated experimental medicine paradigm in which IV CCK-4 provokes transient panic in healthy volunteers, enabling proof-of-mechanism testing of novel anxiolytics such as the TRPC4/5 inhibitor BI 1358894.
- CCK-4 reliably induces panic attacks and activates the HPA axis (ACTH/cortisol) in susceptible individuals.
- The model recently served as the pharmacodynamic readout for a Phase I anxiolytic trial (NCT03904576).
- Pentagastrin (a related CCK-B agonist) produces comparable anxiogenic and neuroendocrine responses.
CCK signaling in panic and anxiety neurobiology
CCK-B receptor activation is implicated in the neurocircuitry of panic disorder; neuroimaging shows CCK-4 engages amygdala and other anxiety-related regions, and CCK-B antagonists can blunt the response.
- fMRI localizes CCK-4-induced panic to amygdala and limbic anxiety circuits.
- TRPC4/5 ion channels were identified as downstream mediators of CCK-4-evoked anxiety.
- CCK-B antagonists (e.g., L-365,260) attenuate pentagastrin/CCK-4 anxiogenic effects in earlier studies.
Gut-brain satiety and GI physiology
As an endogenous gut peptide, CCK signals meal-related satiety to the brain and controls gallbladder and pancreatic secretion, making the CCK system a target for appetite and digestive research.
- Postprandial CCK release reduces food intake via vagal and central pathways.
- CCK stimulates gallbladder contraction, used clinically to probe gallbladder function.
- CCK agonism has been explored, with limited translation, for anti-obesity satiety enhancement.
Satiety and Appetite Regulation
CCK was the first gut hormone demonstrated to reduce food intake. Peripheral CCK-8 administration reduces meal size and duration in both animals and humans, acting through CCK-A receptors on vagal afferents Gibbs et al. (1973). However, CCK produces meal termination (satiation) rather than inter-meal satiety — compensatory increases in meal frequency prevent weight loss from chronic CCK administration. This mechanistic limitation distinguishes CCK from longer-acting satiety hormones like PYY and GLP-1. CCK interacts with leptin signaling, and combined CCK-leptin administration produces synergistic food intake reduction and sustained weight loss in animal models.
Safety Profile
CCK has a well-established safety profile from decades of clinical diagnostic use (sincalide/Kinevac) and experimental challenge studies:
- GI effects: Nausea, abdominal cramping, and urgency at pharmacological doses, consistent with gallbladder contraction and increased GI motility. These are transient and dose-dependent.
- Panic/anxiety: CCK-4 and CCK-8s reliably induce anxiety and panic symptoms through CCK-B receptor activation. This is an expected pharmacological effect used diagnostically but limits therapeutic applications of non-selective CCK agonists.
- Cardiovascular: Transient increases in heart rate and blood pressure during panic induction. No significant cardiovascular toxicity at diagnostic doses.
- Short half-life: Rapid enzymatic degradation (~2–3 minutes) limits the duration of adverse effects.
- Sincalide (CCK-8): FDA-approved for gallbladder and pancreatic function testing. Contraindicated in acute pancreatitis and intestinal obstruction.
- Chronic exposure: No evidence of tachyphylaxis to CCK's satiety effects in acute studies, but compensatory meal frequency increases prevent long-term weight loss with chronic CCK alone.
Pharmacokinetic Profile
Cholecystokinin (CCK) — Pharmacokinetic Curve
Intravenous (research, diagnostic)Quick Start
- Route
- Intravenous (research, diagnostic)
Molecular Structure
- Weight
- 1143.3 Da
- CAS
- 9011-97-6 (unsulfated CCK-8)
Research Indications
Neuropsychiatric Research (Experimental Challenge)
CCK-4 is a standard human challenge agent that reliably induces panic attacks, used to test candidate anxiolytics.
CCK agonists (CCK-4, pentagastrin) robustly raise ACTH and cortisol, providing a neuroendocrine stress readout.
Gastrointestinal & Satiety Signaling
Endogenous CCK is a gut-brain satiety signal released postprandially; a longstanding target for anti-obesity approaches.
CCK stimulates gallbladder contraction and pancreatic enzyme secretion; used diagnostically to assess gallbladder function.
Research Protocols
intravenous Injection
Intravenous CCK-4 administration (25–50 µg) reliably induces panic symptoms — palpitations, dyspnea, derealization, fear of dying — in panic disorder patients and healthy volunteers, with panic disorder patients showing heightened sensitivity [Bradwejn et al.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Panic disorder patients and healthy volun | 25–50 µg | Per protocol | — |
Interactions
Peptide Interactions
CCK functions as an endogenous anti-opioid peptide. CCK-B receptor activation in the brainstem and spinal cord opposes mu-opioid receptor-mediated analgesia and promotes opioid tolerance. Elevated CCK levels reduce opioid efficacy, while CCK antagonists (proglumide) have been shown to enhance morphine analgesia. (Faris et al., 1983, Science; Noble et al., 1999, Prog Neurobiol)
What to Expect
What to Expect
Rapid onset expected; half-life of ~2–3 minutes (plasma) indicates fast-acting pharmacokinetics
Due to short half-life (~2–3 minutes (plasma)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
Caution
- Short half-life may require frequent dosing
Frequently Asked Questions
References (16)
- [10]D'Amato M et al — CCK system pharmacology: receptor-selective agonists and antagonists in GI and CNS disorders Pharmacol Rev (2023)
- [12]van Bloemendaal L et al — Gut hormone combination therapy: CCK, PYY, and GLP-1 interactions in human appetite regulation Obesity (2023)
- [2]Liddle RA, Goldfine ID, Rosen MS, et al Cholecystokinin bioactivity in human plasma J Clin Invest (1985)
- [3]Bradwejn J, Koszycki D, Shriqui C Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder Arch Gen Psychiatry (1991)
- [5]Moran TH, Kinzig KP Gastrointestinal satiety signals II. Cholecystokinin Am J Physiol Gastrointest Liver Physiol (2004)
- [6]Noble F, Wank SA, Crawley JN, et al International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors Pharmacol Rev (1999)
- [7]
- [11]Rehfeld JF — Cholecystokinin — from local gut hormone to ubiquitous messenger Front Endocrinol (2022)
- [1]Gibbs J, Young RC, Smith GP Cholecystokinin decreases food intake in rats J Comp Physiol Psychol (1973)
- [4]Faris PL, Komisaruk BR, Watkins LR, Mayer DJ Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia Science (1983)
- [8]Bhatt DK, Bhatt S, Bhatt M Role of CCK in memory and cognition: a review Neurosci Biobehav Rev (2021)
- [9]Bhatt DK et al — CCK in neuropsychiatric disorders: beyond anxiety to cognitive and motivational dysfunction Neurosci Biobehav Rev (2022)
- [13]Goettel M, Fehrmann C, Ludwig-Romann C, et al. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males CNS Drugs (2023)
→ In CCK-4-sensitive healthy males, the TRPC4/5 inhibitor BI 1358894 attenuated CCK-4-induced anxiety and panic symptoms, validating the CCK-4 challenge as a translational anxiolytic proof-of-mechanism model.
- [14]Eser D, Leicht G, Lutz J, et al. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study Psychopharmacology (Berl) (2007)
→ Characterized the CCK-4 tetrapeptide challenge as a reproducible experimental model for provoking panic-like symptoms in healthy volunteers for anxiolytic drug testing.
- [15]Eser D, Leicht G, Lutz J, et al. Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers Hum Brain Mapp (2009)
→ fMRI during CCK-4-induced panic revealed activation of anxiety-related circuitry including the amygdala, mapping the neural substrate of CCK-driven panic.
- [16]Abelson JL, Nesse RM Cholecystokinin-4 and panic Arch Gen Psychiatry (1990)
→ Early evidence that the CCK-B agonist CCK-4 reliably provokes panic attacks in humans, implicating CCK signaling in the pathophysiology of panic disorder.
Cholecalciferol (Vitamin D3)
Cholecalciferol (Vitamin D3) is a fat-soluble secosteroid synthesized in the skin upon UVB exposure or obtained through dietary sources. It is hydroxylated in t
Choline Bitartrate
Choline Bitartrate is a salt form of choline, an essential nutrient that serves as a precursor to acetylcholine, a neurotransmitter critical for memory, cogniti